For nearly 20 years, Jazz has been at the forefront of pioneering innovative medicines for rare, hard-to-treat disorders. Building on our long history in sleep medicine, we have evolved our research and development, expanding our portfolio to include therapies for oncology and epilepsy. We remain focused on delivering transformative solutions to people for whom we can have the greatest impact.
At the core of our growing expertise and groundbreaking discoveries in neuroscience and oncology is our scientific exploration. Science is the bedrock of innovation, driving advancements in our growing pipeline including movement disorders, psychiatry and neurodegenerative diseases, as well as hematologic and solid tumor cancers. In our relentless pursuit of innovating to transform patients’ lives, we continually work to expand the science behind our existing treatments and explore next-generation therapies, partnering with researchers, academia, healthcare providers, patients and advocacy to advance novel treatments that have the potential to create new or better standards of care.
Harnessing our spirit of exploring uncharted paths and challenging conventional wisdom, Jazz is launching Pioneering Pathways, an interactive series intended to raise awareness and showcase the people, and pioneering research, behind Jazz’s unique scientific approach. Too often, the people and innovative thinking behind some of the biggest therapeutic breakthroughs are overlooked. This includes the scientists and researchers who discover a new mechanism of action, to the patients that were involved in clinical trials.
Pioneering Pathways was created to “lift the veil” behind the unique strategy and pioneering science driving some of Jazz’s leading pipeline assets. Coupled with interviews and engaging animations, Pioneering Pathways aims to give a behind-the-scenes look at the stories and insights driving the development journey for Jazz’s robust pipeline.
To honor Jazz’s longstanding expertise in sleep medicine and pursuit of innovation, the first episode focuses on an underrecognized sleep disorder, idiopathic hypersomnia. Although many patients are misunderstood and often misdiagnosed with other disorders, idiopathic hypersomnia is distinct, multi-symptom, neurologic sleep disorder characterized by key symptoms including sleep inertia and non-restorative, unrefreshing sleep.
Our inaugural episode features voices from across the community, including Meghan, who lives with idiopathic hypersomnia, on how the sleep disorder manifests daily, as well as patient and advocate Diana Kimmel of the Hypersomnia Foundation on how the patient advocacy group gives a voice to patients. The video also includes Richard Bogan, MD, FCCP, FAASM, sharing background on the disorder and Robert Iannone, Executive Vice President, Global Head of Research and Development on Jazz’s R&D commitment to research in idiopathic hypersomnia.
Rooted in science, we will continue to invest in developing new medicines, particularly for underserved communities, with a goal to bring patients options that help them live happier, healthier, and more fulfilled lives. We are pioneering pathways, keeping the eternal flame of innovation alive as we pave the way for remarkable scientific discoveries that benefit our patients and turn the impossible into reality.
Over the next few months, we look forward to expanding the series, offering an inside look at the strategy and science behind our research in other key therapeutic areas of focus. Keep an eye out on Jazz’s channels to learn more about our innovative research as part of Pioneering Pathways.
